WARNING: (A) BLEEDING RISK, (B) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS A. BLEEDING RISK BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding Do not use BRILINTA in patients ... Read More
Assessment of IPA over 8 hours after 180-mg loading dose2,3
In a multicenter, randomized, double-blind study, patients with stable coronary artery disease (CAD) who were taking aspirin therapy (75 mg to 100 mg per day) received BRILINTA (180-mg loading dose, 90-mg twice-daily maintenance dose), clopidogrel (600-mg loading dose, 75-mg once-daily maintenance dose), or placebo for 6 weeks.1
Assessment of IPA after the last dose following 6 weeks on placebo, ticagrelor 90 mg twice daily, or clopidogrel 75 mg daily
BID=twice daily.
QD=once daily.
BRILINTA is indicated to reduce the rate of cardiovascular death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. For at least the first 12 months following ACS, it is superior to clopidogrel.
BRILINTA also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.
In the management of ACS, initiate BRILINTA treatment with a 180-mg loading dose. Administer 90 mg twice daily during the first year after an ACS event. After one year administer 60 mg twice daily. Use BRILINTA with a daily maintenance dose of aspirin of 75-100 mg.
Please read Medication Guide and Prescribing Information, including Boxed WARNINGS, for BRILINTA.